Characterization of novel carcinoma cell lines for the analysis of therapeutical strategies fighting pancreatic cancer.
Dietmar ZechnerFlorian BürtinJonas AmmeTobias LindnerTobias RadeckeStefan HadlichJens-Peter KühnBrigitte VollmarPublished in: Cell & bioscience (2015)
All three cell lines can be used in vitro for testing combinatorial therapies with gemcitabine. The 6606PDA and 6606l cell lines but not the 7265PDA cell line can be used for evaluating distinct therapies in a syngeneic carcinoma model using C57BL/6J mice. Diffusion-weighted MRI proved to be an appropriate method to predict tumor remission.